Prostanoid therapy for pulmonary arterial hypertension: A meta-analysis of survival outcomes

European Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2014, Pages 13-21

  Zheng, Yaguo ^a   Yang, Tao ^a   Chen, Guo ^a   Hu, Enci ^a   Gu, Qing ^a   Xiong, Changming ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Meta analysis; Prostanoids; Pulmonary arterial hypertension; Randomized controlled trials

Indexed keywords

BERAPROST; BOSENTAN; ILOPROST; PROSTACYCLIN; PROSTANOID; TREPROSTINIL;

DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FOLLOW UP; HEART INDEX; HUMAN; INCIDENCE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; META ANALYSIS; MORTALITY; OVERALL SURVIVAL; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIX MINUTE WALK DISTANCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WALKING;

ANTIHYPERTENSIVE AGENTS; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PROSTAGLANDINS; WALKING;

EID: 84891885437     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1583-8     Document Type: Review

References (37)

1. Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493-2537
2. Benza RL, Miller DP, Barst RJ et al (2012) An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142:448-456
3. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Eng J Med 351:1425-1436 (Pubitemid 39302645)
4. Christman BW, McPherson CD, Newman JH et al (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Eng J Med 327:70-75
5. Higenbottam T, Wheeldon D, Wells F et al (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1:1046-1047 (Pubitemid 14148935)
6. Gomberg-Maitland M, Olschewski H (2008) Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31:891-901
7. Jing ZC, Parikh K, Pulido T et al (2013) Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation 127:624-633
8. Tapson VF, Torres F, Kermeen F et al (2012) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial. Chest 142:1383-1390
9. Gabler NB, French B, Strom BL et al (2012) Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126:349-356
10. Savarese G, Paolillo S, Costanzo P et al (2012) Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 60:1192-1201
11. Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Eng J Med 334:296-301 (Pubitemid 26033085)
12. Galie N, Manes A, Negro L et al (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394-403
13. Macchia A, Marchioli R, Marfisi R et al (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153:1037-1047 (Pubitemid 46809838)
14. Ryerson CJ, Nayar S, Swiston JR et al (2010) Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 11:12
15. Li T, Chen Y, Zang W et al (2013) Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Curr Med Res Opin 29:889-999
16. Hiremath J, Thanikachalam S, Parikh K et al (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung transpl 29:137-149
17. McLaughlin VV, Benza RL, Rubin LJ et al (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915-1922
18. McLaughlin VV, Oudiz RJ, Frost A et al (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174:1257-1263 (Pubitemid 44924827)
19. Hoeper MM, Leuchte H, Halank M et al (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28:691-694 (Pubitemid 46331988)
20. McLaughlin VV, Gaine SP, Barst RJ et al (2003) Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293-299 (Pubitemid 36135255)
21. Barst RJ, McGoon M, McLaughlin V et al (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119-2125 (Pubitemid 36724255)
22. Simonneau G, Barst RJ, Galie N et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med 165:800-804 (Pubitemid 34229650)
23. Olschewski H, Simonneau G, Galie N et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Eng J Med 347:322-329 (Pubitemid 34815354)
24. Galie N, Humbert M, Vachiery JL et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496-1502 (Pubitemid 34439066)
25. Badesch DB, Tapson VF, McGoon MD et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425-434 (Pubitemid 30149039)
26. Rubin LJ, Mendoza J, Hood M et al (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485-491 (Pubitemid 20100285)
27. Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43-54
28. Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12 (Pubitemid 26120810)
29. Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1-30
30. Whitlock RP, Chan S, Devereaux PJ et al (2008) Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 29:2592-2600
31. Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634 (Pubitemid 27387172)
32. Rubenfire M, McLaughlin VV, Allen RP et al (2007) Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 132:757-763
33. He B, Zhang F, Li X et al (2010) Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74:1458-1464
34. Barst RJ, Galie N, Naeije R et al (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28:1195-1203 (Pubitemid 44883856)
35. Sitbon O, Humbert M, Nunes H et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780-788 (Pubitemid 34925627)
36. Bai Y, Sun L, Hu S et al (2011) Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology 120:157-165
37. Galie N, Simonneau G, Barst RJ et al (2010) Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med 16[Suppl 1]:S11-19